1. Educational lecture

Recent Trends in Clinical and Nonclinical Human Risk Assessment of QT Interval Prolongation for New Chemical Entities and Regulatory Perspectives on Risk Evaluation

Satoshi Tsunoda (Pharmaceuticals and Medical Devices Agency）

2. SymposiumⅠ:Application of novel Technologies in Central Nervous System Evaluation

① The Future of Pharmacotoxicology: Data-Driven Animal Experiments with AI Behavioral Analysis

Takahisa Murata (Veterinary Pharmacology, Animal Radiology, Food and Animal Systemics, Agricultural and Life Sciences, The University of Tokyo）

② Development of human iPSc-derived brain microvascular endothelial cells for drug evaluation

Tadahiro Hashita (Graduate School of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University）

3. SymposiumⅡ: Application of novel Technologies in Cardiovascular Evaluation

① Advances in Cardiovascular Safety Pharmacology using NAMs: Perspectives toward the ICH S7A Revision（tentative）

Yasunari Kanda (Division of Pharmacology, National Institute of Health Sciences (NIHS))

② Simulation study of cardiac arrhythmia using electro physiologically and anatomically detailed heart model - from single cell model to large scale tissue model -

Shin Inada (Department of Medical Engineering, Faculty of Medical Science Technology, Morinomiya University of Medical Sciences）

4. Case Study ：Safety Evaluation Strategies in Drug Development -Let's learn from Other Companies-

① Late-onset QT prolongation observed in an NHP general toxicity study.

Keisuke Yoshinaga (Safety Research Laboratories, Tanabe Pharma Corporation)

② Nausea and vomiting that non-clinical toxicity studies failed to predict

Satoru Kajikawa (Early Development & Translational Science Applied Research & Nonclinical Safety, Astellas Pharma Inc.)

5. Workshop: Current topics and outlook of proarrhythmic assessment of drug-induced QT prolongation with the best practice under ICHS7B Q&A (Panel discussion)

Satoshi Tsunoda (Pharmaceuticals and Medical Devices Agency）

Ryuichi Komatsu (Safety and Bioscience Research Dept., CHUGAI PHAMACEUTICAL CO., LTD.)

Katsuhiko Sakai (Application Support Research Support Dept., PRIMETECH CORPORATION)

Hiromi Negishi (Safety Assessment Department, Drug Discovery Regulatory Center, Mediford Corporation)

Fumiyuki Nakane (Non-Clinical Research Department, CMIC Pharma Science Co., Ltd)

Masayuki Yamada (Clinical Development Div., KISSEI PHARMACEUTICAL CO., LTD.)

Hiroyasu Miyazaki （Safety Pharmacology, DMPK & Safety BU, Axcelead Drug Discovery Partners, Inc.）

6. Luncheon Seminar

7. Invited lecture from overseas

Concordance between cardiovascular effects in telemetry studies, toxicity studies, and early clinical trials

Greiter-Wilke, Andrea (F. Hoffman-La Roche)

8. General lecture (Poster presentation, Flush talk, Best Presentation Award）

9.Exhibition（Exhibition booths, Flush talk）